Davis Capital Management
ANIP icon

Davis Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Davis Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1
Closed -$83 – 1185
2026
Q2 		$83 Buy
+1
New +$80 ﹤0.01% 1104

Other funds holding ANIP

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Penn Capital Management
Penn Capital Management Philadelphia, Pennsylvania $1.37B AUM 42.56% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Thompson Siegel & Walmsley
Thompson Siegel & Walmsley Richmond, Virginia $5.37B AUM 3.99% 1-Year Est. Return
Marathon Capital Management
Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return
Bridge City Capital
Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Davis Capital Management's ANIP Position: Q3 2026 in Review

Davis Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q3 2026, closing a stake of 1 share — an estimated $83 sold.

Davis Capital Management first reported a position in ANIP in Q2 2026 and held it in 1 quarter. The position peaked at $83 in Q2 2026. 94 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Davis Capital Management reported no remaining ANI Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Davis Capital Management sold 1 ANI Pharmaceuticals share in Q3 2026, an estimated $83.
  • Davis Capital Management first reported a position in ANI Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Davis Capital Management's ANI Pharmaceuticals position peaked at $83 in Q2 2026.
  • 94 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.